The Japanese group pays $120m for Anima’s preclinical small-molecule approach.
The nascent company hopes to prove that its inhaled pan-Jak is best in class.
The failure of OV101 puts the spotlight on Ultragenyx and Roche.
Sanofi goes all in on Kiadis's natural killer cell projects, gained through an all-stock deal in 2019.
Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.
Shortly after canning its lead and acquiring the NK cell company Cytosen, Kiadis flips part of the tech to Sanofi.